CATX

0.74375.14%
JM

Johan M. Spoor

CEO & Director

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc. in June 2014. He served as Non-Independent Director of AzurRx BioPharma, Inc since May 14, 2014 until April 29, 2020. He served as Chief Executive Officer at Viewpoint Molecular Targeting, Inc. until February 03, 2023. Prior to joining Viewpoint, Mr. Spoor served as the President and CEO of KBP Biosciences, a global, clinical-stage biotechnology company focused on discovering, developing and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases. While at KBP Biosciences, Mr. Spoor led all operations for major fund-raising and IPO readiness and drove small molecule clinical development programs, including toxicology, clinical pharmacology, Phase 2 studies and discussions with regulators. He served as the Chief Executive Officer and President of AzurRx BioPharma, Inc. since January 2016 and April 2015 respectively until October 8, 2019. Mr. Spoor served as the Chief Operating Officer at AzurRx BioPharma, Inc. He served as the Chief Executive Officer of FluoroPharma Medical, Inc. since February 14, 2011 until December 29, 2015 and served as its President since February 14, 2011 until October 05, 2015. Previously, Mr. Spoor served as the Chief Financial Officer of FluoroPharma Medical, Inc. until August 2012 and also served as its Chief Accounting Officer. He has 15 years of international experience in the medical industry across a variety of roles including Regulatory Affairs and New Product Development. He was the Chief Financial Officer for Sunstone BioSciences from February 2010 to September 2010. Prior to joining Sunstone BioSciences, he worked as a Consultant at Oliver Wyman from December 2008 to February 2010, focusing on helping pharmaceutical and medical device companies evaluate their global revenue potential given the complex interplay of regulatory approvals, the reimbursement environment, as well as the impact of physician preference within constantly evolving standards of care. He further specialized on the implications of healthcare reform on new product approval and health insurance reform. He also spent few years on Wall Street as an equity research analyst at J.P. Morgan and Credit Suisse, where he covered biotechnology and medical device stocks. Mr. Spoor served as a Research Analyst of Cr?dit Suisse AG, Research Division. He served as an Associate of JP Morgan Chase & Co, Research Division. He was an Equity Research Analyst at J.P. Morgan from July 2007 to October 2008 and Credit Suisse from November 2005 to July 2007, covering the biotechnology and medical device industries. Prior to his career on Wall Street, Mr. Spoor worked in the pharmaceutical industry spending 11 years with Amersham / GE Healthcare where he worked in 7 countries in a variety of roles including setting up GMP facilities, accountability for the nuclear cardiology portfolio and as the Director of New Product Opportunities leading the PET strategic plan. He served as the Global Brand Head for Nuclear Cardiology at GE Healthcare. He served as the Chairman of AzurRx BioPharma, Inc from June 2014 to September 2015. He served as the Chairman of FluoroPharma Medical, Inc. since June 14, 2012 until December 29, 2015. Mr. Spoor served as the Chairman of MetaStat, Inc. (former Name: Photovoltaic Solar Cells Inc) from 2012 to October 15, 2014 and served as its Independent Director since April 7, 2012 until August 31, 2016. He has been an Independent Director of Atheronova Inc. since January 3, 2012. He has been a Director at Protea Biosciences, Inc. since January 28, 2013 and FluoraPharma Medical Inc. since September 2010. Mr. Spoor also serves on the board of directors of Verifi Water, Inc. He served as Director of FluoroPharma Medical, Inc. from February 14, 2011 to January 1, 2017. He served as a Director of Protea Biosciences Group, Inc from January 28, 2013 to August 18, 2014. He is trained as a Nuclear Pharmacist. He has been a guest lecturer at Columbia Business School, Kings College in London and the University of Newcastle in Australia. Mr. Spoor holds an MBA from Columbia Business School and Columbia University with concentrations in finance and accounting and holds a Nuclear Pharmacy Degree from the University of Toronto.

Positions